Ken Griffin Karyopharm Therapeutics Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Karyopharm Therapeutics Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 64,000 shares of KPTI stock, worth $49,920. This represents 0.0% of its overall portfolio holdings.

Number of Shares

64,000

Previous 79,600 19.6%

Holding current value

$49,920

Previous $69,000 23.19%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$0.7 - $1.06 $1,589 - $2,406	2,270 Added 0.07%	3,103,669 $2.58 Million
Q2 2024 Aug 14, 2024	SELL	$0.87 - $1.58 $3,192 - $5,798	-3,670 Reduced 0.12%	3,101,399 $2.7 Million
Q1 2024 May 15, 2024	BUY	$0.72 - $1.66 $2,642 - $6,092	3,670 Added 0.12%	3,105,069 $4.69 Million
Q4 2023 Feb 14, 2024	SELL	$0.68 - $1.31 $1,692 - $3,260	-2,489 Reduced 0.08%	3,101,399 $2.67 Million
Q3 2023 Nov 14, 2023	SELL	$1.14 - $1.81 $52,205 - $82,887	-45,794 Reduced 1.45%	3,103,888 $4.16 Million
Q2 2023 Aug 14, 2023	SELL	$1.79 - $4.59 $810,472 - $2.08 Million	-452,778 Reduced 12.57%	3,149,682 $5.64 Million
Q1 2023 May 15, 2023	SELL	$2.84 - $3.92 $314,368 - $433,916	-110,693 Reduced 2.98%	3,602,460 $14 Million
Q4 2022 Feb 14, 2023	BUY	$2.48 - $5.93 $4.72 Million - $11.3 Million	1,903,507 Added 105.19%	3,713,153 $12.6 Million
Q3 2022 Nov 14, 2022	BUY	$4.08 - $5.82 $5.72 Million - $8.16 Million	1,401,297 Added 343.16%	1,809,646 $9.88 Million
Q2 2022 Aug 15, 2022	SELL	$4.15 - $8.37 $1.85 Million - $3.73 Million	-446,168 Reduced 52.21%	408,349 $1.84 Million
Q1 2022 May 16, 2022	BUY	$5.91 - $14.38 $3.7 Million - $9 Million	625,634 Added 273.34%	854,517 $6.3 Million
Q4 2021 Feb 14, 2022	BUY	$5.21 - $8.61 $42,232 - $69,792	8,106 Added 3.67%	228,883 $1.47 Million
Q3 2021 Nov 15, 2021	BUY	$4.45 - $10.63 $43,089 - $102,930	9,683 Added 4.59%	220,777 $1.29 Million
Q2 2021 Aug 16, 2021	SELL	$8.11 - $11.11 $4.96 Million - $6.79 Million	-611,422 Reduced 74.34%	211,094 $2.18 Million
Q1 2021 May 17, 2021	BUY	$9.85 - $17.69 $5.37 Million - $9.65 Million	545,441 Added 196.86%	822,516 $8.65 Million
Q4 2020 Feb 16, 2021	SELL	$14.15 - $17.19 $9.2 Million - $11.2 Million	-650,363 Reduced 70.12%	277,075 $4.29 Million
Q3 2020 Nov 16, 2020	BUY	$14.14 - $19.71 $11.1 Million - $15.5 Million	788,306 Added 566.59%	927,438 $13.5 Million
Q2 2020 Aug 14, 2020	SELL	$16.6 - $25.25 $22.7 Million - $34.5 Million	-1,367,171 Reduced 90.76%	139,132 $2.64 Million
Q1 2020 May 15, 2020	BUY	$14.38 - $27.72 $1.63 Million - $3.14 Million	113,309 Added 8.13%	1,506,303 $28.9 Million
Q4 2019 Feb 14, 2020	SELL	$9.23 - $19.67 $1.27 Million - $2.71 Million	-137,595 Reduced 8.99%	1,392,994 $26.7 Million
Q3 2019 Nov 14, 2019	BUY	$5.66 - $11.85 $3.68 Million - $7.7 Million	649,656 Added 73.75%	1,530,589 $14.7 Million
Q2 2019 Aug 14, 2019	SELL	$4.32 - $6.43 $3.94 Million - $5.86 Million	-911,471 Reduced 50.85%	880,933 $5.28 Million
Q1 2019 May 15, 2019	BUY	$4.12 - $10.25 $6.35 Million - $15.8 Million	1,540,334 Added 611.07%	1,792,404 $0
Q4 2018 Feb 14, 2019	BUY	$8.2 - $16.95 $89,814 - $185,653	10,953 Added 4.54%	252,070 $2.36 Million
Q3 2018 Nov 13, 2018	BUY	$17.03 - $21.18 $1.1 Million - $1.37 Million	64,755 Added 36.72%	241,117 $0
Q2 2018 Aug 10, 2018	BUY	$12.0 - $19.88 $989,064 - $1.64 Million	82,422 Added 87.74%	176,362 $0
Q1 2018 May 11, 2018	BUY	$9.92 - $17.25 $393,149 - $683,652	39,632 Added 72.98%	93,940 $1.26 Million
Q4 2017 Feb 09, 2018	BUY	$9.15 - $11.99 $313,643 - $410,993	34,278 Added 171.13%	54,308 $521,000
Q3 2017 Nov 09, 2017	BUY	$8.15 - $11.16 $163,244 - $223,534	20,030	20,030 $220,000

Others Institutions Holding KPTI

# of Institutions

Shares Held

57.6M

Call Options Held

258K

Put Options Held

81.2K

View Full List

About Karyopharm Therapeutics Inc.

Ticker KPTI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 79,806,600
Market Cap $62.2M
Description
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...

More about KPTI

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account